MAPK6, mitogen-activated protein kinase 6, 5597

N. diseases: 40; N. variants: 4
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0020507
Disease: Hyperplasia
Hyperplasia
0.300 Biomarker phenotype CTD_human Early induction of cytokines/cytokine receptors and Cox2, and activation of NF-κB in 4-nitroquinoline 1-oxide-induced murine oral cancer model. 22561872 2012
CUI: C0410702
Disease: Adolescent idiopathic scoliosis
Adolescent idiopathic scoliosis
0.100 GeneticVariation disease GWASCAT The coexistence of copy number variations (CNVs) and single nucleotide polymorphisms (SNPs) at a locus can result in distorted calculations of the significance in associating SNPs to disease. 30019117 2018
SCOLIOSIS, ISOLATED, SUSCEPTIBILITY TO, 3
0.100 GeneticVariation disease GWASCAT The coexistence of copy number variations (CNVs) and single nucleotide polymorphisms (SNPs) at a locus can result in distorted calculations of the significance in associating SNPs to disease. 30019117 2018
CUI: C0003868
Disease: Arthritis, Gouty
Arthritis, Gouty
0.100 GeneticVariation disease GWASCAT Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. 25676789 2015
CUI: C0018099
Disease: Gout
Gout
0.100 GeneticVariation disease GWASCAT Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. 25676789 2015
CUI: C0202239
Disease: Uric acid measurement (procedure)
Uric acid measurement (procedure)
0.100 GeneticVariation phenotype GWASCAT Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. 25676789 2015
CUI: C4021107
Disease: Non-obstructive azoospermia
Non-obstructive azoospermia
0.100 GeneticVariation disease GWASDB A genome-wide association study reveals that variants within the HLA region are associated with risk for nonobstructive azoospermia. 22541561 2012
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.050 AlteredExpression disease BEFREE For instance, ERK3 upregulates matrix metallopeptidases and thereby promotes cancer cell invasiveness, and it phosphorylates tyrosyl-DNA phosphodiesterase 2, thereby enhancing chemoresistance in lung cancer. 30569573 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.050 AlteredExpression disease BEFREE For instance, ERK3 upregulates matrix metallopeptidases and thereby promotes cancer cell invasiveness, and it phosphorylates tyrosyl-DNA phosphodiesterase 2, thereby enhancing chemoresistance in lung cancer. 30569573 2019
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung
0.050 AlteredExpression disease BEFREE For instance, ERK3 upregulates matrix metallopeptidases and thereby promotes cancer cell invasiveness, and it phosphorylates tyrosyl-DNA phosphodiesterase 2, thereby enhancing chemoresistance in lung cancer. 30569573 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.050 AlteredExpression disease BEFREE Activation loop phosphorylation of ERK3 is important for its kinase activity and ability to promote lung cancer cell invasiveness. 30166347 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.050 AlteredExpression disease BEFREE Activation loop phosphorylation of ERK3 is important for its kinase activity and ability to promote lung cancer cell invasiveness. 30166347 2018
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung
0.050 AlteredExpression disease BEFREE Activation loop phosphorylation of ERK3 is important for its kinase activity and ability to promote lung cancer cell invasiveness. 30166347 2018
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.050 GeneticVariation disease BEFREE In the present study, we functionally and mechanistically characterized ERK3 L290P/V mutations, which are located within ERK3's kinase domain, and are shown to exist in several cancers including lung cancer and colon cancer. 29101390 2017
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.050 GeneticVariation disease BEFREE In the present study, we functionally and mechanistically characterized ERK3 L290P/V mutations, which are located within ERK3's kinase domain, and are shown to exist in several cancers including lung cancer and colon cancer. 29101390 2017
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung
0.050 GeneticVariation disease BEFREE In the present study, we functionally and mechanistically characterized ERK3 L290P/V mutations, which are located within ERK3's kinase domain, and are shown to exist in several cancers including lung cancer and colon cancer. 29101390 2017
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.050 Biomarker disease BEFREE ERK3 regulates TDP2-mediated DNA damage response and chemoresistance in lung cancer cells. 26701725 2016
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.050 Biomarker disease BEFREE ERK3 regulates TDP2-mediated DNA damage response and chemoresistance in lung cancer cells. 26701725 2016
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung
0.050 Biomarker disease BEFREE ERK3 regulates TDP2-mediated DNA damage response and chemoresistance in lung cancer cells. 26701725 2016
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.050 Biomarker disease BEFREE As such, ERK3 protein kinase may be an attractive target for therapeutic treatment of invasive lung cancer. 22505454 2012
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.050 Biomarker disease BEFREE As such, ERK3 protein kinase may be an attractive target for therapeutic treatment of invasive lung cancer. 22505454 2012
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung
0.050 Biomarker disease BEFREE As such, ERK3 protein kinase may be an attractive target for therapeutic treatment of invasive lung cancer. 22505454 2012
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.040 AlteredExpression group BEFREE Interestingly, a catalytically inactive ERK3 mutant was still capable of increasing migration and invasion, although to a lesser extent compared with WT ERK3, suggesting that ERK3 promotes cancer cell invasiveness by both kinase-dependent and kinase-independent mechanisms. 30166347 2018
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.040 AlteredExpression group BEFREE Interestingly, a catalytically inactive ERK3 mutant was still capable of increasing migration and invasion, although to a lesser extent compared with WT ERK3, suggesting that ERK3 promotes cancer cell invasiveness by both kinase-dependent and kinase-independent mechanisms. 30166347 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.040 Biomarker group BEFREE ERK3 then acts as an important downstream mediator of BMI1 in promoting cancer cell migration. 28079973 2017